Neurochemical evidence that stimulation of CB1 cannabinoid receptors on GABAergic nerve terminals activates the dopaminergic reward system by increasing dopamine release in the rat nucleus accumbens

We examined the effect of cannabinoid receptor activation on basal and electrical field simulation-evoked (25 V, 2 Hz, 240 shocks) [ 3H]dopamine efflux in the isolated rat nucleus accumbens in a preparation, in which any effect on the dendrites or somata of ventral tegmental projection neurons was e...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neurochemistry international 2009-06, Vol.54 (7), p.452-457
Hauptverfasser: Sperlágh, Beáta, Windisch, Katalin, Andó, Rómeó D., Sylvester Vizi, E.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 457
container_issue 7
container_start_page 452
container_title Neurochemistry international
container_volume 54
creator Sperlágh, Beáta
Windisch, Katalin
Andó, Rómeó D.
Sylvester Vizi, E.
description We examined the effect of cannabinoid receptor activation on basal and electrical field simulation-evoked (25 V, 2 Hz, 240 shocks) [ 3H]dopamine efflux in the isolated rat nucleus accumbens in a preparation, in which any effect on the dendrites or somata of ventral tegmental projection neurons was excluded. The cannabinoid agonist (R)-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenylmethanone mesylate (WIN55,212-2, 100 nM) significantly enhanced stimulation-evoked [ 3H]dopamine release in the presence of the selective dopamine transporter inhibitor 1-[2-[bis-(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine dihydrochloride (GBR12909, 100 nM). GBR12909 (100 nM–1 μM), when added alone, increased the evoked [ 3H]dopamine efflux in a concentration-dependent manner. The stimulatory effect of WIN55,212-2 on the evoked tritium efflux was inhibited by the selective CB1 cannabinoid receptor antagonist N-(piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (AM251, 100 nM) and by the GABA A receptor antagonist bicuculline (10 μM). Repeated application of N-methyl- d aspartate (1 mM) under Mg 2+-free conditions, which directly acts on dopaminergic terminals, reversibly increased the tritium efflux, but WIN55,212-2 did not affect N-methyl- d aspartate-evoked [ 3H]dopamine efflux, indicating that WIN55,212-2 has no direct action on dopaminergic nerve terminals. AM251 (100 nM) alone also did not have an effect on electrical stimulation-evoked [ 3H]dopamine efflux. Likewise, the selective CB2 receptor antagonist 6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl)methanone (AM630, 0.3 μM) and the anandamide transport inhibitor (5Z,8Z,11Z,14Z)-N-(4-hydroxy-2-methylphenyl)-5,8,11,14-eicosatetraenamide (VDM11, 10 μM) had no significant effect on electrically evoked [ 3H]dopamine release. This is the first neurochemical evidence that the activation of CB1 cannabinoid receptors leads to the augmentation of [ 3H]dopamine efflux via a local GABA A receptor-mediated disinhibitory mechanism in the rat nucleus accumbens.
doi_str_mv 10.1016/j.neuint.2009.01.017
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67228845</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0197018609000357</els_id><sourcerecordid>20068399</sourcerecordid><originalsourceid>FETCH-LOGICAL-c421t-bb943afc2c45990f66dfc4c51c00d7b0684d01744b8c17b5b3f7a3cea4d77a873</originalsourceid><addsrcrecordid>eNqFksFu1DAQhiMEokvhDRDyBW5Z7MSJ7QvSdgUtUgUXOFvOeNJ6lTiL7Wy1L8hz4XRX5QbSSJY83_z-Nb-L4i2ja0ZZ-3G39jg7n9YVpWpNWS7xrFgxKapSiYY_L1aUKVFSJtuL4lWMO0qpULR5WVwwxSsppFwVv7_hHCa4x9GBGQgenEUPSNK9SSQmN86DSW7yZOrJ9ooRMN6bzvnJWRIQcJ-mEEnuX2-uNhjuHBCP4ZAFMIzOmyESA8kdTMKYRZHYaW9y44QGfDDBkniMCUfSHYnzENBE5--ewAwN-Qpz71EgZGN-hgHnRRrmsUMfXxcv-vwWvjmfl8XPL59_bG_K2-_XX7eb2xJ4xVLZdYrXpocKeKMU7dvW9sChYUCpFR1tJbd5jZx3Epjomq7uhakBDbdCGCnqy-LDSXcfpl8zxqRHFwGHwXic5qhbUVVS8ua_YA6tlbVSGeQnEMIUY8Be74MbTThqRvUStN7pU9DLjNKU5VqMvDvrz92I9u_QOdkMvD8DJuZk-2A8uPjEVayWnMvF6KcTh3ltB4dBR3DLF7Au55u0ndy_nfwB1iHOOA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20068399</pqid></control><display><type>article</type><title>Neurochemical evidence that stimulation of CB1 cannabinoid receptors on GABAergic nerve terminals activates the dopaminergic reward system by increasing dopamine release in the rat nucleus accumbens</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Sperlágh, Beáta ; Windisch, Katalin ; Andó, Rómeó D. ; Sylvester Vizi, E.</creator><creatorcontrib>Sperlágh, Beáta ; Windisch, Katalin ; Andó, Rómeó D. ; Sylvester Vizi, E.</creatorcontrib><description>We examined the effect of cannabinoid receptor activation on basal and electrical field simulation-evoked (25 V, 2 Hz, 240 shocks) [ 3H]dopamine efflux in the isolated rat nucleus accumbens in a preparation, in which any effect on the dendrites or somata of ventral tegmental projection neurons was excluded. The cannabinoid agonist (R)-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenylmethanone mesylate (WIN55,212-2, 100 nM) significantly enhanced stimulation-evoked [ 3H]dopamine release in the presence of the selective dopamine transporter inhibitor 1-[2-[bis-(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine dihydrochloride (GBR12909, 100 nM). GBR12909 (100 nM–1 μM), when added alone, increased the evoked [ 3H]dopamine efflux in a concentration-dependent manner. The stimulatory effect of WIN55,212-2 on the evoked tritium efflux was inhibited by the selective CB1 cannabinoid receptor antagonist N-(piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (AM251, 100 nM) and by the GABA A receptor antagonist bicuculline (10 μM). Repeated application of N-methyl- d aspartate (1 mM) under Mg 2+-free conditions, which directly acts on dopaminergic terminals, reversibly increased the tritium efflux, but WIN55,212-2 did not affect N-methyl- d aspartate-evoked [ 3H]dopamine efflux, indicating that WIN55,212-2 has no direct action on dopaminergic nerve terminals. AM251 (100 nM) alone also did not have an effect on electrical stimulation-evoked [ 3H]dopamine efflux. Likewise, the selective CB2 receptor antagonist 6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl)methanone (AM630, 0.3 μM) and the anandamide transport inhibitor (5Z,8Z,11Z,14Z)-N-(4-hydroxy-2-methylphenyl)-5,8,11,14-eicosatetraenamide (VDM11, 10 μM) had no significant effect on electrically evoked [ 3H]dopamine release. This is the first neurochemical evidence that the activation of CB1 cannabinoid receptors leads to the augmentation of [ 3H]dopamine efflux via a local GABA A receptor-mediated disinhibitory mechanism in the rat nucleus accumbens.</description><identifier>ISSN: 0197-0186</identifier><identifier>EISSN: 1872-9754</identifier><identifier>DOI: 10.1016/j.neuint.2009.01.017</identifier><identifier>PMID: 19428788</identifier><identifier>CODEN: NEUIDS</identifier><language>eng</language><publisher>Kidlington: Elsevier Ltd</publisher><subject>Anandamide ; Animals ; Benzoxazines - pharmacology ; Bicuculline - pharmacology ; Biological and medical sciences ; Cannabinoid ; CB1 receptor ; Dopamine ; Dopamine - metabolism ; Dopamine - physiology ; Electric Stimulation ; Fundamental and applied biological sciences. Psychology ; GABA ; GABA Antagonists - pharmacology ; GABA-A Receptor Antagonists ; gamma-Aminobutyric Acid - physiology ; Male ; Morpholines - pharmacology ; Naphthalenes - pharmacology ; Nerve Endings - drug effects ; Nucleus accumbens ; Nucleus Accumbens - drug effects ; Nucleus Accumbens - metabolism ; Piperidines - pharmacology ; Pyrazoles - pharmacology ; Rats ; Rats, Wistar ; Receptor, Cannabinoid, CB1 - agonists ; Release ; Reward ; Vertebrates: nervous system and sense organs</subject><ispartof>Neurochemistry international, 2009-06, Vol.54 (7), p.452-457</ispartof><rights>2009 Elsevier Ltd</rights><rights>2009 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c421t-bb943afc2c45990f66dfc4c51c00d7b0684d01744b8c17b5b3f7a3cea4d77a873</citedby><cites>FETCH-LOGICAL-c421t-bb943afc2c45990f66dfc4c51c00d7b0684d01744b8c17b5b3f7a3cea4d77a873</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.neuint.2009.01.017$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=21384485$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19428788$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sperlágh, Beáta</creatorcontrib><creatorcontrib>Windisch, Katalin</creatorcontrib><creatorcontrib>Andó, Rómeó D.</creatorcontrib><creatorcontrib>Sylvester Vizi, E.</creatorcontrib><title>Neurochemical evidence that stimulation of CB1 cannabinoid receptors on GABAergic nerve terminals activates the dopaminergic reward system by increasing dopamine release in the rat nucleus accumbens</title><title>Neurochemistry international</title><addtitle>Neurochem Int</addtitle><description>We examined the effect of cannabinoid receptor activation on basal and electrical field simulation-evoked (25 V, 2 Hz, 240 shocks) [ 3H]dopamine efflux in the isolated rat nucleus accumbens in a preparation, in which any effect on the dendrites or somata of ventral tegmental projection neurons was excluded. The cannabinoid agonist (R)-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenylmethanone mesylate (WIN55,212-2, 100 nM) significantly enhanced stimulation-evoked [ 3H]dopamine release in the presence of the selective dopamine transporter inhibitor 1-[2-[bis-(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine dihydrochloride (GBR12909, 100 nM). GBR12909 (100 nM–1 μM), when added alone, increased the evoked [ 3H]dopamine efflux in a concentration-dependent manner. The stimulatory effect of WIN55,212-2 on the evoked tritium efflux was inhibited by the selective CB1 cannabinoid receptor antagonist N-(piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (AM251, 100 nM) and by the GABA A receptor antagonist bicuculline (10 μM). Repeated application of N-methyl- d aspartate (1 mM) under Mg 2+-free conditions, which directly acts on dopaminergic terminals, reversibly increased the tritium efflux, but WIN55,212-2 did not affect N-methyl- d aspartate-evoked [ 3H]dopamine efflux, indicating that WIN55,212-2 has no direct action on dopaminergic nerve terminals. AM251 (100 nM) alone also did not have an effect on electrical stimulation-evoked [ 3H]dopamine efflux. Likewise, the selective CB2 receptor antagonist 6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl)methanone (AM630, 0.3 μM) and the anandamide transport inhibitor (5Z,8Z,11Z,14Z)-N-(4-hydroxy-2-methylphenyl)-5,8,11,14-eicosatetraenamide (VDM11, 10 μM) had no significant effect on electrically evoked [ 3H]dopamine release. This is the first neurochemical evidence that the activation of CB1 cannabinoid receptors leads to the augmentation of [ 3H]dopamine efflux via a local GABA A receptor-mediated disinhibitory mechanism in the rat nucleus accumbens.</description><subject>Anandamide</subject><subject>Animals</subject><subject>Benzoxazines - pharmacology</subject><subject>Bicuculline - pharmacology</subject><subject>Biological and medical sciences</subject><subject>Cannabinoid</subject><subject>CB1 receptor</subject><subject>Dopamine</subject><subject>Dopamine - metabolism</subject><subject>Dopamine - physiology</subject><subject>Electric Stimulation</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>GABA</subject><subject>GABA Antagonists - pharmacology</subject><subject>GABA-A Receptor Antagonists</subject><subject>gamma-Aminobutyric Acid - physiology</subject><subject>Male</subject><subject>Morpholines - pharmacology</subject><subject>Naphthalenes - pharmacology</subject><subject>Nerve Endings - drug effects</subject><subject>Nucleus accumbens</subject><subject>Nucleus Accumbens - drug effects</subject><subject>Nucleus Accumbens - metabolism</subject><subject>Piperidines - pharmacology</subject><subject>Pyrazoles - pharmacology</subject><subject>Rats</subject><subject>Rats, Wistar</subject><subject>Receptor, Cannabinoid, CB1 - agonists</subject><subject>Release</subject><subject>Reward</subject><subject>Vertebrates: nervous system and sense organs</subject><issn>0197-0186</issn><issn>1872-9754</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFksFu1DAQhiMEokvhDRDyBW5Z7MSJ7QvSdgUtUgUXOFvOeNJ6lTiL7Wy1L8hz4XRX5QbSSJY83_z-Nb-L4i2ja0ZZ-3G39jg7n9YVpWpNWS7xrFgxKapSiYY_L1aUKVFSJtuL4lWMO0qpULR5WVwwxSsppFwVv7_hHCa4x9GBGQgenEUPSNK9SSQmN86DSW7yZOrJ9ooRMN6bzvnJWRIQcJ-mEEnuX2-uNhjuHBCP4ZAFMIzOmyESA8kdTMKYRZHYaW9y44QGfDDBkniMCUfSHYnzENBE5--ewAwN-Qpz71EgZGN-hgHnRRrmsUMfXxcv-vwWvjmfl8XPL59_bG_K2-_XX7eb2xJ4xVLZdYrXpocKeKMU7dvW9sChYUCpFR1tJbd5jZx3Epjomq7uhakBDbdCGCnqy-LDSXcfpl8zxqRHFwGHwXic5qhbUVVS8ua_YA6tlbVSGeQnEMIUY8Be74MbTThqRvUStN7pU9DLjNKU5VqMvDvrz92I9u_QOdkMvD8DJuZk-2A8uPjEVayWnMvF6KcTh3ltB4dBR3DLF7Au55u0ndy_nfwB1iHOOA</recordid><startdate>20090601</startdate><enddate>20090601</enddate><creator>Sperlágh, Beáta</creator><creator>Windisch, Katalin</creator><creator>Andó, Rómeó D.</creator><creator>Sylvester Vizi, E.</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7U7</scope><scope>C1K</scope><scope>7X8</scope></search><sort><creationdate>20090601</creationdate><title>Neurochemical evidence that stimulation of CB1 cannabinoid receptors on GABAergic nerve terminals activates the dopaminergic reward system by increasing dopamine release in the rat nucleus accumbens</title><author>Sperlágh, Beáta ; Windisch, Katalin ; Andó, Rómeó D. ; Sylvester Vizi, E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c421t-bb943afc2c45990f66dfc4c51c00d7b0684d01744b8c17b5b3f7a3cea4d77a873</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Anandamide</topic><topic>Animals</topic><topic>Benzoxazines - pharmacology</topic><topic>Bicuculline - pharmacology</topic><topic>Biological and medical sciences</topic><topic>Cannabinoid</topic><topic>CB1 receptor</topic><topic>Dopamine</topic><topic>Dopamine - metabolism</topic><topic>Dopamine - physiology</topic><topic>Electric Stimulation</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>GABA</topic><topic>GABA Antagonists - pharmacology</topic><topic>GABA-A Receptor Antagonists</topic><topic>gamma-Aminobutyric Acid - physiology</topic><topic>Male</topic><topic>Morpholines - pharmacology</topic><topic>Naphthalenes - pharmacology</topic><topic>Nerve Endings - drug effects</topic><topic>Nucleus accumbens</topic><topic>Nucleus Accumbens - drug effects</topic><topic>Nucleus Accumbens - metabolism</topic><topic>Piperidines - pharmacology</topic><topic>Pyrazoles - pharmacology</topic><topic>Rats</topic><topic>Rats, Wistar</topic><topic>Receptor, Cannabinoid, CB1 - agonists</topic><topic>Release</topic><topic>Reward</topic><topic>Vertebrates: nervous system and sense organs</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sperlágh, Beáta</creatorcontrib><creatorcontrib>Windisch, Katalin</creatorcontrib><creatorcontrib>Andó, Rómeó D.</creatorcontrib><creatorcontrib>Sylvester Vizi, E.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>MEDLINE - Academic</collection><jtitle>Neurochemistry international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sperlágh, Beáta</au><au>Windisch, Katalin</au><au>Andó, Rómeó D.</au><au>Sylvester Vizi, E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Neurochemical evidence that stimulation of CB1 cannabinoid receptors on GABAergic nerve terminals activates the dopaminergic reward system by increasing dopamine release in the rat nucleus accumbens</atitle><jtitle>Neurochemistry international</jtitle><addtitle>Neurochem Int</addtitle><date>2009-06-01</date><risdate>2009</risdate><volume>54</volume><issue>7</issue><spage>452</spage><epage>457</epage><pages>452-457</pages><issn>0197-0186</issn><eissn>1872-9754</eissn><coden>NEUIDS</coden><abstract>We examined the effect of cannabinoid receptor activation on basal and electrical field simulation-evoked (25 V, 2 Hz, 240 shocks) [ 3H]dopamine efflux in the isolated rat nucleus accumbens in a preparation, in which any effect on the dendrites or somata of ventral tegmental projection neurons was excluded. The cannabinoid agonist (R)-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenylmethanone mesylate (WIN55,212-2, 100 nM) significantly enhanced stimulation-evoked [ 3H]dopamine release in the presence of the selective dopamine transporter inhibitor 1-[2-[bis-(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine dihydrochloride (GBR12909, 100 nM). GBR12909 (100 nM–1 μM), when added alone, increased the evoked [ 3H]dopamine efflux in a concentration-dependent manner. The stimulatory effect of WIN55,212-2 on the evoked tritium efflux was inhibited by the selective CB1 cannabinoid receptor antagonist N-(piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (AM251, 100 nM) and by the GABA A receptor antagonist bicuculline (10 μM). Repeated application of N-methyl- d aspartate (1 mM) under Mg 2+-free conditions, which directly acts on dopaminergic terminals, reversibly increased the tritium efflux, but WIN55,212-2 did not affect N-methyl- d aspartate-evoked [ 3H]dopamine efflux, indicating that WIN55,212-2 has no direct action on dopaminergic nerve terminals. AM251 (100 nM) alone also did not have an effect on electrical stimulation-evoked [ 3H]dopamine efflux. Likewise, the selective CB2 receptor antagonist 6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl)methanone (AM630, 0.3 μM) and the anandamide transport inhibitor (5Z,8Z,11Z,14Z)-N-(4-hydroxy-2-methylphenyl)-5,8,11,14-eicosatetraenamide (VDM11, 10 μM) had no significant effect on electrically evoked [ 3H]dopamine release. This is the first neurochemical evidence that the activation of CB1 cannabinoid receptors leads to the augmentation of [ 3H]dopamine efflux via a local GABA A receptor-mediated disinhibitory mechanism in the rat nucleus accumbens.</abstract><cop>Kidlington</cop><pub>Elsevier Ltd</pub><pmid>19428788</pmid><doi>10.1016/j.neuint.2009.01.017</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0197-0186
ispartof Neurochemistry international, 2009-06, Vol.54 (7), p.452-457
issn 0197-0186
1872-9754
language eng
recordid cdi_proquest_miscellaneous_67228845
source MEDLINE; Access via ScienceDirect (Elsevier)
subjects Anandamide
Animals
Benzoxazines - pharmacology
Bicuculline - pharmacology
Biological and medical sciences
Cannabinoid
CB1 receptor
Dopamine
Dopamine - metabolism
Dopamine - physiology
Electric Stimulation
Fundamental and applied biological sciences. Psychology
GABA
GABA Antagonists - pharmacology
GABA-A Receptor Antagonists
gamma-Aminobutyric Acid - physiology
Male
Morpholines - pharmacology
Naphthalenes - pharmacology
Nerve Endings - drug effects
Nucleus accumbens
Nucleus Accumbens - drug effects
Nucleus Accumbens - metabolism
Piperidines - pharmacology
Pyrazoles - pharmacology
Rats
Rats, Wistar
Receptor, Cannabinoid, CB1 - agonists
Release
Reward
Vertebrates: nervous system and sense organs
title Neurochemical evidence that stimulation of CB1 cannabinoid receptors on GABAergic nerve terminals activates the dopaminergic reward system by increasing dopamine release in the rat nucleus accumbens
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T04%3A04%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Neurochemical%20evidence%20that%20stimulation%20of%20CB1%20cannabinoid%20receptors%20on%20GABAergic%20nerve%20terminals%20activates%20the%20dopaminergic%20reward%20system%20by%20increasing%20dopamine%20release%20in%20the%20rat%20nucleus%20accumbens&rft.jtitle=Neurochemistry%20international&rft.au=Sperl%C3%A1gh,%20Be%C3%A1ta&rft.date=2009-06-01&rft.volume=54&rft.issue=7&rft.spage=452&rft.epage=457&rft.pages=452-457&rft.issn=0197-0186&rft.eissn=1872-9754&rft.coden=NEUIDS&rft_id=info:doi/10.1016/j.neuint.2009.01.017&rft_dat=%3Cproquest_cross%3E20068399%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=20068399&rft_id=info:pmid/19428788&rft_els_id=S0197018609000357&rfr_iscdi=true